Tudor Investment Corp ET AL Takes Position in LivaNova PLC $LIVN

Tudor Investment Corp ET AL purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 33,332 shares of the company’s stock, valued at approximately $1,746,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Arizona State Retirement System increased its stake in LivaNova by 1.7% during the third quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock worth $845,000 after acquiring an additional 274 shares during the last quarter. Bayforest Capital Ltd lifted its stake in shares of LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after purchasing an additional 284 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after purchasing an additional 306 shares during the period. California State Teachers Retirement System grew its holdings in shares of LivaNova by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after purchasing an additional 458 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in shares of LivaNova by 31.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 1,901 shares of the company’s stock worth $100,000 after purchasing an additional 460 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LIVN has been the topic of several research analyst reports. Barclays boosted their price objective on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Mizuho lifted their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. KeyCorp initiated coverage on shares of LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective on the stock. Finally, Needham & Company LLC increased their price objective on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Price Performance

LIVN opened at $61.85 on Friday. The stock’s 50-day moving average price is $64.91 and its 200 day moving average price is $60.14. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $71.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -13.87 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. The company had revenue of $360.92 million during the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s revenue was up 12.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, sell-side analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.